Loading
HKSEHealthcareBiotechnology
Latest quote
HK$5.285
+HK$0.09 · +1.73%
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Latest quote
HK$5.285
+HK$0.09 · +1.73%
Regular session · HKT · Market data may be delayed.
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Day range
Current HK$5.285
52-week range
Current HK$5.285
Regular session · HKT · Market data may be delayed.
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Day range
Current HK$5.285
52-week range
Current HK$5.285
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 269.58M CNY | 407.21M CNY | 463.84M CNY | 481.36M CNY | 243.72M CNY |
| Cost of goods sold | 218.34M CNY | 167.05M CNY | 159.55M CNY | 202.99M CNY | 106.83M CNY |
| Gross profit | 51.25M CNY | 240.15M CNY | 304.3M CNY | 278.38M CNY | 136.89M CNY |
| Research and development | 311.5M CNY | 134.66M CNY | 527.8M CNY | 614.16M CNY | 1.3B CNY |
| Selling, general, and administrative | 172.36M CNY | 166.94M CNY | 248.07M CNY | 390.48M CNY | 472.99M CNY |
| Operating expenses | 483.87M CNY | 331.85M CNY | 909.86M CNY | 1.19B CNY | 1.97B CNY |
| Interest income | 10.12M CNY | 12.67M CNY | 24.89M CNY | 9.67M CNY | 9.8M CNY |
| Interest expense | 12.93M CNY | 15.17M CNY | 11.82M CNY | 8.48M CNY | 2.24M CNY |
| Depreciation and amortization | 11.98M CNY | 18.93M CNY | 58.19M CNY | 44.54M CNY | 22.66M CNY |
| Operating income | −432.62M CNY | −91.69M CNY | −605.57M CNY | −912.15M CNY | −1.83B CNY |
| Net income | −437M CNY | −91.21M CNY | −367.23M CNY | −902.68M CNY | −1.92B CNY |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
